HealthQuill Merck KGaA
Germany’s Merck KGaA, is set to acquire biopharmaceutical company SpringWorks Therapeutics Inc. for $3.9 billion in cash to add rare tumour therapies to its portfolio.
Drugs Medical Pharma

Merck to buy SpringWorks for $3.9b to add rare tumour medicines

HQ Team April 29, 2025: Germany’s Merck KGaA, is set to acquire biopharmaceutical company SpringWorks Therapeutics Inc. for $3.9 billion in cash to.

Read More